This post was originally published on this site
“This new ambition does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023,” Sanofi said in a statement.
This month, analysts at investment bank JP Morgan had said they expected Sanofi to raise its peak sales guidance for Dupixent to about $15 billion.
Sanofi is working with British partner GlaxoSmithKline (NYSE:GSK) to develop a COVID-19 vaccine.
Sanofi also announced on Tuesday a partnership with U.S company IGM Biosciences (NASDAQ:IGMS) in the field of treatments for oncology, immunology and inflammation.
($1=0.9096 euros)
